Edgewise Therapeutics EWTX 深 沪
已收盘 09-26 16:00:00 美东时间
16.05
+1.165
+7.83%
华盛通- 最 高16.53
- 今 开14.71
- 成交量 126.54万股
- 最 低 14.67
- 昨 收 14.885
- 总市值 16.85亿
- 52周最高 38.12
- 市盈率 静 --
- 换手率 1.21%
- 52周最低 10.60
- 委 比 98.87%
- 总股本 1.05亿
- 历史最高 40.49
- 量 比 0.94
- 振 幅 12.50%
- 历史最低 5.12
- 每 手 1
- 风险率 7.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多JP Morgan Maintains Overweight on Edgewise Therapeutics, Lowers Price Target to $30
JP Morgan analyst Tessa Romero maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Overweight and lowers the price target from $40 to $30.
08-19 22:31
Analysts’ Top Healthcare Picks: Immunic (IMUX), Edgewise Therapeutics (EWTX)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
08-12 18:20
美股机会日报丨逼近历史高点！比特币突破12万美元大关；花旗看多标普500指数目标价至6600点
逼近历史高点！比特币突破12万美元大关，美股加密货币概念普涨；花旗看多标普500指数目标价至6600点；AMC院线盘前大涨近10%，公司Q2财报大超预期>>
08-11 20:37
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $49
RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $48 to $49.
08-09 01:44
Edgewise Therapeutics GAAP EPS of -$0.34
Edgewise Therapeutics press release (NASDAQ:EWTX): Q2 GAAP EPS of -$0.34. Cash, cash equivalents and marketable securities were approximately $594.0 million as of June 30, 2025. More on Edgewise The...
08-07 21:17
Edgewise Therapeutics Q2 EPS $(0.34) Beats $(0.43) Estimate
Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.43) by 20.19 percent. This is unchanged from the same period last year.
08-07 20:11
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
BOULDER, Colo., Aug. 6, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel th...
08-07 04:02
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
07-01 09:24
Edgewise falls after data for muscular dystrophy therapy
Edgewise Therapeutics (NASDAQ:EWTX) lost ~9% in the morning hours on Thursday after the company posted data from clinical trials for its lead asset, sevasemten, against Becker and Duchenne muscular dy...
06-26 22:20
